<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<addis-data xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://drugis.org/files/addis-6.xsd">
    <units>
        <unit name="gram" symbol="g"/>
        <unit name="liter" symbol="l"/>
    </units>
    <indications>
        <indication code="38341003" name="Hypertensive disorder"/>
    </indications>
    <drugs>
        <drug name="Azilsartan" atcCode="C09CA09"/>
        <drug name="Olmesartan" atcCode="C09CA08"/>
        <drug name="Placebo" atcCode="Placebo"/>
    </drugs>
    <treatmentCategorizations/>
    <endpoints>
        <endpoint name="DBP 12-hour mean" description="Change from baseline in the 12-hour mean diastolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="DBP 24-hour mean" description="Change from baseline in the 24-hour mean diastolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="DBP daytime mean" description="Change from baseline in daytime (6am - 10pm) mean diastolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="DBP mean trough (clinic, sitting)" description="Change from baseline in mean trough clinic sitting diastolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="DBP nighttime mean" description="Change from baseline in the nighttime (12am - 6am) mean diastolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="DBP response (clinic)" description="Participants who achieve a clinic diastolic blood pressure response, defined as &lt; 90 mmHg and/or reduction from baseline at least 10 mmHg" direction="HIGHER_IS_BETTER">
            <rate/>
        </endpoint>
        <endpoint name="DBP trough mean" description="Change from baseline in the trough (22-24hr) mean diastolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="SBP 12-hour mean" description="Change from baseline in the 12-hour mean systolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="SBP 24-hour mean" description="Change from baseline in the 24-hour mean systolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="SBP and DBP response (clinic)" description="Participants who achieve both clinic SBP and clinic DBP response" direction="HIGHER_IS_BETTER">
            <rate/>
        </endpoint>
        <endpoint name="SBP daytime mean" description="Change from baseline in daytime (6am - 10pm) mean systolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="SBP mean trough (clinic, sitting)" description="Change from baseline in mean trough clinic sitting systolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="SBP nighttime mean" description="Change from baseline in nighttime (12am - 6am) mean systolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="SBP response (clinic)" description="Participants who achieve a clinic systolic blood pressure response, defined as &lt; 140 mmHg and/or reduction frome baseline at least 20 mmHg" direction="HIGHER_IS_BETTER">
            <rate/>
        </endpoint>
        <endpoint name="SBP trough mean" description="Change from baseline in the trough (22-24hr) mean systolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
    </endpoints>
    <adverseEvents>
        <adverseEvent name="Atrial fibrillation" description="Atrial fibrillation (Cardiac disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Cellulitis" description="Cellulitis (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Chest pain" description="Chest pain (General disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Cholecystitis chronic" description="Cholecystitis chronic (Hepatobiliary disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Coronary artery disease" description="Coronary artery disease (Cardiac disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Dyslipidemia" description="Dyslipidemia (Metabolism and nutrition disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Epilepsy" description="Epilepsy (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Gastrointestinal haemorrhage" description="Gastrointestinal haemorrhage (Gastrointestinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Headache" description="Headache (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Inguinal hernia" description="Inguinal hernia (Gastrointestinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Ischaemia" description="Ischaemia (Vascular disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Ischaemic stroke" description="Ischaemic stroke (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Lower respiratory tract infection" description="Lower respiratory tract infection (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Myelodysplastic syndrome" description="Myelodysplastic syndrome (Neoplasms benign, malignant and unspecified (incl cysts and polyps))" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Myocardial infarction" description="Myocardial infarction (Cardiac disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Non-SAE" description="Non-serious adverse events (total)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Pneumonia" description="Pneumonia (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="SAE" description="Serious adverse events" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Shock" description="Shock (Vascular disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Status asthmaticus" description="Status asthmaticus (Respiratory, thoracic and mediastinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Transient ischaemic attack" description="Transient ischaemic attack (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
    </adverseEvents>
    <populationCharacteristics>
        <populationCharacteristic name="Age (cut-off 45, 65)" description="Age in years">
            <categorical>
                <category>&lt; 45</category>
                <category>45-64</category>
                <category>&gt; 64</category>
            </categorical>
        </populationCharacteristic>
        <populationCharacteristic name="Gender" description="Gender (male, female)">
            <categorical>
                <category>Female</category>
                <category>Male</category>
            </categorical>
        </populationCharacteristic>
    </populationCharacteristics>
    <studies>
        <study name="NCT00696241">
            <indication name="Hypertensive disorder">
                <notes>
                    <note source="CLINICALTRIALS">Hypertension</note>
                </notes>
            </indication>
            <characteristics>
                <title>
                    <value>Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension</value>
                    <notes>
                        <note source="CLINICALTRIALS">Brief title: Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

Official title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Subjects With Essential Hypertension</note>
                    </notes>
                </title>
                <allocation>
                    <value>RANDOMIZED</value>
                    <notes>
                        <note source="CLINICALTRIALS">Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</note>
                    </notes>
                </allocation>
                <blinding>
                    <value>DOUBLE_BLIND</value>
                    <notes>
                        <note source="CLINICALTRIALS">Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</note>
                    </notes>
                </blinding>
                <centers>
                    <value>85</value>
                    <notes>
                        <note source="CLINICALTRIALS">Birmingham, Alabama, United States
Huntsville, Alabama, United States
Mesa, Arizona, United States
Phoenix, Arizona, United States
Tempe, Arizona, United States
Little Rock, Arkansas, United States
Tempe, Arkansas, United States
Beverly Hills, California, United States
Carmichael, California, United States
Fountain Valley, California, United States
Long Beach, California, United States
Los Gatos, California, United States
Orangevale, California, United States
Sacramento, California, United States
Santa Ana, California, United States
Spring Valley, California, United States
Tustin, California, United States
Westlake Village, California, United States
Colorado Springs, Colorado, United States
Farmington, Connecticut, United States
Hollywood, Florida, United States
Jacksonville, Florida, United States
Jupiter, Florida, United States
Melbourne, Florida, United States
Miami, Florida, United States
Naples, Florida, United States
Ocala, Florida, United States
Pembroke Pines, Florida, United States
Sarasota, Florida, United States
St. Petersburg, Florida, United States
Augusta, Georgia, United States
Lawrenceville, Georgia, United States
Chicago, Illinois, United States
Melrose Park, Illinois, United States
Naperville, Illinois, United States
Round Lake Beach, Illinois, United States
Valparaiso, Indiana, United States
Wichita, Kansas, United States
Erlanger, Kentucky, United States
Lexington, Kentucky, United States
Auburn, Maine, United States
West Yarmouth, Massachusetts, United States
Benzonia, Michigan, United States
Chelsea, Michigan, United States
Omaha, Nebraska, United States
Trenton, New Jersey, United States
Wildwood Crest, New Jersey, United States
Albuquerque, New Mexico, United States
Brooklyn, New York, United States
Orangevale, New York, United States
Rochester, New York, United States
Burlington, North Carolina, United States
Charlotte, North Carolina, United States
Raleigh, North Carolina, United States
Salisbury, North Carolina, United States
Statesville, North Carolina, United States
Wilmington, North Carolina, United States
Winston-Salem, North Carolina, United States
Kettering, Ohio, United States
Lyndhurst, Ohio, United States
Marion, Ohio, United States
Norman, Oklahoma, United States
Oklahoma City, Oklahoma, United States
Altoona, Pennsylvania, United States
Reading, Pennsylvania, United States
Mt. Pleasant, South Carolina, United States
Simpsonville, South Carolina, United States
Taylors, South Carolina, United States
Nashville, Tennessee, United States
New Tazewell, Tennessee, United States
Dallas, Texas, United States
Houston, Texas, United States
Lake Jackson, Texas, United States
North Richland Hills, Texas, United States
San Antonio, Texas, United States
Draper, Utah, United States
Burke, Virginia, United States
Norfolk, Virginia, United States
Tacoma, Washington, United States
Madison, Wisconsin, United States
Provincia de Buenos Aires, Argentina
Provincia de Cordoba, Argentina
Aguascalientes,, Mexico
Mexico DF, Mexico
San Luis Potosi, Mexico
</note>
                    </notes>
                </centers>
                <objective>
                    <value>The purpose of this study is to determine the safety and efficacy of azilsartan medoxomil,once daily (QD), compared to placebo and olmesartan in participants with essentialhypertension.</value>
                    <notes>
                        <note source="CLINICALTRIALS">The purpose of this study is to determine the safety and efficacy of azilsartan medoxomil,once daily (QD), compared to placebo and olmesartan in participants with essentialhypertension.</note>
                    </notes>
                </objective>
                <study_start>
                    <value>2007-06-01</value>
                    <notes>
                        <note source="CLINICALTRIALS">June 2007</note>
                    </notes>
                </study_start>
                <study_end>
                    <value>2008-10-01</value>
                    <notes>
                        <note source="CLINICALTRIALS">October 2008</note>
                    </notes>
                </study_end>
                <status>
                    <value>COMPLETED</value>
                    <notes>
                        <note source="CLINICALTRIALS">Completed</note>
                    </notes>
                </status>
                <inclusion>
                    <value>1. Has essential hypertension (defined as sitting trough clinic systolic blood pressurebetween 150 and 180 mm Hg, inclusive at Day minus 1) and 24-hour mean systolic bloodpressure greater than or equal to 130 mm Hg and less than or equal to 170 mm Hg atDay 1).

2. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study.

3. Clinical laboratory evaluations (including clinical chemistry, hematology, andcomplete urinalysis) within the reference range for the testing laboratory or theresults are deemed not clinically significant for inclusion into this study by theinvestigator.

4. The subject is willing to discontinue current antihypertensive medications at theScreening Day minus 21 visit. If the subject is on amlodipine prior to screening, thesubject is willing to discontinue this medication at Screening Day minus 28.</value>
                    <notes>
                        <note source="CLINICALTRIALS">Inclusion Criteria

1. Has essential hypertension (defined as sitting trough clinic systolic blood pressurebetween 150 and 180 mm Hg, inclusive at Day minus 1) and 24-hour mean systolic bloodpressure greater than or equal to 130 mm Hg and less than or equal to 170 mm Hg atDay 1).

2. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study.

3. Clinical laboratory evaluations (including clinical chemistry, hematology, andcomplete urinalysis) within the reference range for the testing laboratory or theresults are deemed not clinically significant for inclusion into this study by theinvestigator.

4. The subject is willing to discontinue current antihypertensive medications at theScreening Day minus 21 visit. If the subject is on amlodipine prior to screening, thesubject is willing to discontinue this medication at Screening Day minus 28.

Exclusion Criteria

1. Sitting trough clinic diastolic blood pressure greater than 114 mm Hg at Day minus 1.

2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.

3. History of myocardial infarction, heart failure, unstable angina, coronary arterybypass graft, percutaneous coronary intervention, hypertensive encephalopathy,cerebrovascular accident, or transient ischemic attack.

4. Clinically significant cardiac conduction defects (eg, third degree atrioventricularblock, left bundle branch block, sick sinus syndrome, atrial fibrillation or atrialflutter).

5. Hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

6. Secondary hypertension of any etiology.

7. Is noncompliant (less than 70% or greater than 130%) with study medication duringPlacebo Run-In Period.

8. Severe renal dysfunction or disease (based on calculated creatinine clearance lessthan 30 mL/min/1.73 m2) at Screening.

9. Known or suspected unilateral or bilateral renal artery stenosis.

10. History of drug abuse (defined as illicit drug use) or a history of alcohol abuse(defined as regular or daily consumption of more than 2 alcoholic drinks per day)within the past 2 years.

11. History of cancer that has not been in remission for at least 5 years prior to thefirst dose of study drug. (This criterion does not apply to those subjects with basalcell or stage I squamous cell carcinoma of the skin).

12. Type 1 or poorly controlled type 2 diabetes mellitus (glycosylated hemoglobin greaterthan 8.0%) at Screening.

13. Alanine aminotransferase level greater than 2.5 times the upper limit of normal,active liver disease, or jaundice at Screening.

14. Hyperkalemia (defined as serum potassium greater than the upper limit of normal perthe central laboratory) at Screening.

15. Upper arm circumference less than 24 cm or greater than 42 cm.

16. Works night (3rd) shift (defined as 11 PM to 7 AM).

17. Currently participating in another investigational study or has participated in aninvestigational study within 30 days prior to Screening.

18. Any other serious disease or condition at Screening (or Randomization) that wouldcompromise subject safety, might affect life expectancy, or make it difficult tosuccessfully manage and follow the subject according to the protocol.

19. Randomized in a previous azilsartan medoxomil study.</note>
                    </notes>
                </inclusion>
                <exclusion>
                    <value>1. Sitting trough clinic diastolic blood pressure greater than 114 mm Hg at Day minus 1.

2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.

3. History of myocardial infarction, heart failure, unstable angina, coronary arterybypass graft, percutaneous coronary intervention, hypertensive encephalopathy,cerebrovascular accident, or transient ischemic attack.

4. Clinically significant cardiac conduction defects (eg, third degree atrioventricularblock, left bundle branch block, sick sinus syndrome, atrial fibrillation or atrialflutter).

5. Hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

6. Secondary hypertension of any etiology.

7. Is noncompliant (less than 70% or greater than 130%) with study medication duringPlacebo Run-In Period.

8. Severe renal dysfunction or disease (based on calculated creatinine clearance lessthan 30 mL/min/1.73 m2) at Screening.

9. Known or suspected unilateral or bilateral renal artery stenosis.

10. History of drug abuse (defined as illicit drug use) or a history of alcohol abuse(defined as regular or daily consumption of more than 2 alcoholic drinks per day)within the past 2 years.

11. History of cancer that has not been in remission for at least 5 years prior to thefirst dose of study drug. (This criterion does not apply to those subjects with basalcell or stage I squamous cell carcinoma of the skin).

12. Type 1 or poorly controlled type 2 diabetes mellitus (glycosylated hemoglobin greaterthan 8.0%) at Screening.

13. Alanine aminotransferase level greater than 2.5 times the upper limit of normal,active liver disease, or jaundice at Screening.

14. Hyperkalemia (defined as serum potassium greater than the upper limit of normal perthe central laboratory) at Screening.

15. Upper arm circumference less than 24 cm or greater than 42 cm.

16. Works night (3rd) shift (defined as 11 PM to 7 AM).

17. Currently participating in another investigational study or has participated in aninvestigational study within 30 days prior to Screening.

18. Any other serious disease or condition at Screening (or Randomization) that wouldcompromise subject safety, might affect life expectancy, or make it difficult tosuccessfully manage and follow the subject according to the protocol.

19. Randomized in a previous azilsartan medoxomil study.</value>
                    <notes>
                        <note source="CLINICALTRIALS">Inclusion Criteria

1. Has essential hypertension (defined as sitting trough clinic systolic blood pressurebetween 150 and 180 mm Hg, inclusive at Day minus 1) and 24-hour mean systolic bloodpressure greater than or equal to 130 mm Hg and less than or equal to 170 mm Hg atDay 1).

2. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study.

3. Clinical laboratory evaluations (including clinical chemistry, hematology, andcomplete urinalysis) within the reference range for the testing laboratory or theresults are deemed not clinically significant for inclusion into this study by theinvestigator.

4. The subject is willing to discontinue current antihypertensive medications at theScreening Day minus 21 visit. If the subject is on amlodipine prior to screening, thesubject is willing to discontinue this medication at Screening Day minus 28.

Exclusion Criteria

1. Sitting trough clinic diastolic blood pressure greater than 114 mm Hg at Day minus 1.

2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.

3. History of myocardial infarction, heart failure, unstable angina, coronary arterybypass graft, percutaneous coronary intervention, hypertensive encephalopathy,cerebrovascular accident, or transient ischemic attack.

4. Clinically significant cardiac conduction defects (eg, third degree atrioventricularblock, left bundle branch block, sick sinus syndrome, atrial fibrillation or atrialflutter).

5. Hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

6. Secondary hypertension of any etiology.

7. Is noncompliant (less than 70% or greater than 130%) with study medication duringPlacebo Run-In Period.

8. Severe renal dysfunction or disease (based on calculated creatinine clearance lessthan 30 mL/min/1.73 m2) at Screening.

9. Known or suspected unilateral or bilateral renal artery stenosis.

10. History of drug abuse (defined as illicit drug use) or a history of alcohol abuse(defined as regular or daily consumption of more than 2 alcoholic drinks per day)within the past 2 years.

11. History of cancer that has not been in remission for at least 5 years prior to thefirst dose of study drug. (This criterion does not apply to those subjects with basalcell or stage I squamous cell carcinoma of the skin).

12. Type 1 or poorly controlled type 2 diabetes mellitus (glycosylated hemoglobin greaterthan 8.0%) at Screening.

13. Alanine aminotransferase level greater than 2.5 times the upper limit of normal,active liver disease, or jaundice at Screening.

14. Hyperkalemia (defined as serum potassium greater than the upper limit of normal perthe central laboratory) at Screening.

15. Upper arm circumference less than 24 cm or greater than 42 cm.

16. Works night (3rd) shift (defined as 11 PM to 7 AM).

17. Currently participating in another investigational study or has participated in aninvestigational study within 30 days prior to Screening.

18. Any other serious disease or condition at Screening (or Randomization) that wouldcompromise subject safety, might affect life expectancy, or make it difficult tosuccessfully manage and follow the subject according to the protocol.

19. Randomized in a previous azilsartan medoxomil study.</note>
                    </notes>
                </exclusion>
                <references>
                    <pubMedId>21282560</pubMedId>
                    <pubMedId>21272195</pubMedId>
                </references>
                <source>
                    <value>CLINICALTRIALS</value>
                    <notes>
                        <note source="CLINICALTRIALS">http://clinicaltrials.gov/show/NCT00696241</note>
                    </notes>
                </source>
                <creation_date>
                    <value>2012-09-24</value>
                    <notes>
                        <note source="CLINICALTRIALS">Information obtained from ClinicalTrials.gov on September 20, 2012</note>
                    </notes>
                </creation_date>
            </characteristics>
            <studyOutcomeMeasures>
                <studyOutcomeMeasure id="endpoint-SBP 24-hour mean" primary="true">
                    <endpoint name="SBP 24-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)" primary="false">
                    <endpoint name="SBP mean trough (clinic, sitting)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure
Description: The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP 24-hour mean" primary="false">
                    <endpoint name="DBP 24-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)" primary="false">
                    <endpoint name="DBP mean trough (clinic, sitting)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
Description: The change in mean trough clinic sitting diastolic blood pressure measured at final visit or week 6 relative to baseline.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP daytime mean" primary="false">
                    <endpoint name="SBP daytime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP daytime mean" primary="false">
                    <endpoint name="DBP daytime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP nighttime mean" primary="false">
                    <endpoint name="SBP nighttime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP nighttime mean" primary="false">
                    <endpoint name="DBP nighttime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP 12-hour mean" primary="false">
                    <endpoint name="SBP 12-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
Description: The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP 12-hour mean" primary="false">
                    <endpoint name="DBP 12-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
Description: The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP trough mean" primary="false">
                    <endpoint name="SBP trough mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP trough mean" primary="false">
                    <endpoint name="DBP trough mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP response (clinic)" primary="false">
                    <endpoint name="SBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as &lt; 140 mm Hg and/or Reduction From Baseline  20 mm Hg
Description: Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP response (clinic)" primary="false">
                    <endpoint name="DBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as &lt; 90 mm Hg and/or Reduction From Baseline  10 mm Hg
Description: Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)" primary="false">
                    <endpoint name="SBP and DBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response
Description: Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-SAE" primary="false">
                    <adverseEvent name="SAE"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Total, serious adverse events (Total)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation" primary="false">
                    <adverseEvent name="Atrial fibrillation"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Atrial fibrillation (Cardiac disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Coronary artery disease" primary="false">
                    <adverseEvent name="Coronary artery disease"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Coronary artery disease (Cardiac disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Myocardial infarction" primary="false">
                    <adverseEvent name="Myocardial infarction"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Myocardial infarction (Cardiac disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage" primary="false">
                    <adverseEvent name="Gastrointestinal haemorrhage"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Gastrointestinal haemorrhage (Gastrointestinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Inguinal hernia" primary="false">
                    <adverseEvent name="Inguinal hernia"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Inguinal hernia (Gastrointestinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Chest pain" primary="false">
                    <adverseEvent name="Chest pain"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Chest pain (General disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Cholecystitis chronic" primary="false">
                    <adverseEvent name="Cholecystitis chronic"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Cholecystitis chronic (Hepatobiliary disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Cellulitis" primary="false">
                    <adverseEvent name="Cellulitis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Cellulitis (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Lower respiratory tract infection" primary="false">
                    <adverseEvent name="Lower respiratory tract infection"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Lower respiratory tract infection (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Pneumonia" primary="false">
                    <adverseEvent name="Pneumonia"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Pneumonia (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Myelodysplastic syndrome" primary="false">
                    <adverseEvent name="Myelodysplastic syndrome"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Myelodysplastic syndrome (Neoplasms benign, malignant and unspecified (incl cysts and polyps))</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Epilepsy" primary="false">
                    <adverseEvent name="Epilepsy"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Epilepsy (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke" primary="false">
                    <adverseEvent name="Ischaemic stroke"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Ischaemic stroke (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Transient ischaemic attack" primary="false">
                    <adverseEvent name="Transient ischaemic attack"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Transient ischaemic attack (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Status asthmaticus" primary="false">
                    <adverseEvent name="Status asthmaticus"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Status asthmaticus (Respiratory, thoracic and mediastinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Ischaemia" primary="false">
                    <adverseEvent name="Ischaemia"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Ischaemia (Vascular disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Shock" primary="false">
                    <adverseEvent name="Shock"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Shock (Vascular disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Non-SAE" primary="false">
                    <adverseEvent name="Non-SAE"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Total, other adverse events (Total)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Dyslipidemia" primary="false">
                    <adverseEvent name="Dyslipidemia"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Dyslipidemia (Metabolism and nutrition disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Headache" primary="false">
                    <adverseEvent name="Headache"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Headache (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)" primary="false">
                    <populationCharacteristic name="Age (cut-off 45, 65)"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Age
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Gender" primary="false">
                    <populationCharacteristic name="Gender"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Gender
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
            </studyOutcomeMeasures>
            <arms>
                <arm name="Azilsartan Medoxomil 20 mg QD" size="283">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Azilsartan Medoxomil 20 mg QD
Arm Type: Experimental

Intervention Name: Azilsartan medoxomil and olmesartan
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 20 mg, tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.</note>
                    </notes>
                </arm>
                <arm name="Azilsartan Medoxomil 40 mg QD" size="283">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Azilsartan Medoxomil 40 mg QD
Arm Type: Experimental

Intervention Name: Azilsartan medoxomil and olmesartan
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.</note>
                    </notes>
                </arm>
                <arm name="Azilsartan Medoxomil 80 mg QD" size="285">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Azilsartan Medoxomil 80 mg QD
Arm Type: Experimental

Intervention Name: Azilsartan medoxomil and olmesartan
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 80 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.</note>
                    </notes>
                </arm>
                <arm name="Olmesartan 40 mg QD" size="282">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Olmesartan 40 mg QD
Arm Type: Active Comparator

Intervention Name: Olmesartan
Intervention Type: Drug
Intervention Description: Olmesartan 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily for up to 6 weeks.</note>
                    </notes>
                </arm>
                <arm name="Placebo QD" size="142">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Placebo QD
Arm Type: Placebo Comparator

Intervention Name: Placebo
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and olmesartan 40 mg placebo- matching tablets, orally, once daily for up to 6 weeks.</note>
                    </notes>
                </arm>
            </arms>
            <measurements>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-7.72" sampleSize="241" stdDev="8.057046667358954"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-8.63" sampleSize="244" stdDev="8.060177665535667"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.88" sampleSize="243" stdDev="8.059232407617987"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.86" sampleSize="250" stdDev="8.063808033429368"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.47" sampleSize="120" stdDev="8.062476046476045"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-7.47" sampleSize="241" stdDev="7.110072010887091"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-8.38" sampleSize="244" stdDev="7.107327205075055"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.61" sampleSize="243" stdDev="7.108336514262673"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.74" sampleSize="250" stdDev="7.099313347078011"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.69" sampleSize="120" stdDev="7.109438796417057"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-7.71" sampleSize="241" stdDev="7.606845601167412"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-8.43" sampleSize="244" stdDev="7.60718318433308"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.87" sampleSize="243" stdDev="7.607167146842509"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.82" sampleSize="250" stdDev="7.605277772704952"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.59" sampleSize="120" stdDev="7.613343549321809"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-6.82" sampleSize="274" stdDev="8.855825766127065"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-6.86" sampleSize="276" stdDev="8.854861037870668"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.42" sampleSize="279" stdDev="8.852745336899735"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-6.91" sampleSize="280" stdDev="8.85186308073052"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="0.21" sampleSize="140" stdDev="8.862287515083224"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-6.98" sampleSize="241" stdDev="8.274385113106593"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-7.9" sampleSize="244" stdDev="8.278864656461053"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-7.79" sampleSize="243" stdDev="8.277470809371666"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.62" sampleSize="250" stdDev="8.269356081340312"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.96" sampleSize="120" stdDev="8.270610618328009"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="185" sampleSize="274"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="196" sampleSize="276"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="205" sampleSize="279"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="208" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="67" sampleSize="140"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-7.96" sampleSize="241" stdDev="9.531843263503655"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-7.93" sampleSize="244" stdDev="9.528504604606118"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.68" sampleSize="242" stdDev="9.520485701895675"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.56" sampleSize="250" stdDev="9.534267145407663"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.12" sampleSize="120" stdDev="9.530372500589891"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-12.72" sampleSize="241" stdDev="12.34171888352672"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-14.05" sampleSize="244" stdDev="12.340194487932514"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-15.18" sampleSize="243" stdDev="12.330469699082839"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-13.07" sampleSize="250" stdDev="12.33288287465668"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.36" sampleSize="120" stdDev="12.33471199501634"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-12.15" sampleSize="241" stdDev="11.006639859648356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-13.48" sampleSize="244" stdDev="10.996831543676569"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-14.62" sampleSize="243" stdDev="11.005450831292647"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-12.56" sampleSize="250" stdDev="11.00472625738596"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.4" sampleSize="120" stdDev="10.998268954703736"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="117" sampleSize="274"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="125" sampleSize="276"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="145" sampleSize="279"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="133" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="20" sampleSize="140"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-12.57" sampleSize="241" stdDev="11.658655196891278"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-13.75" sampleSize="244" stdDev="11.652892516452727"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-14.96" sampleSize="243" stdDev="11.644577579285562"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-12.73" sampleSize="250" stdDev="11.652993177720477"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.54" sampleSize="120" stdDev="11.655536023709935"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-14.28" sampleSize="274" stdDev="15.824615761527987"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-14.47" sampleSize="276" stdDev="15.815811834996014"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-17.58" sampleSize="279" stdDev="15.818018554800092"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-14.87" sampleSize="280" stdDev="15.812874501494028"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-2.06" sampleSize="140" stdDev="15.819597340008373"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-11.1" sampleSize="241" stdDev="12.12438043777908"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-12.39" sampleSize="244" stdDev="12.105886997655315"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-13.35" sampleSize="243" stdDev="12.11223129732916"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-12.13" sampleSize="250" stdDev="12.111523438444893"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.97" sampleSize="120" stdDev="12.104668520864172"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="131" sampleSize="274"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="139" sampleSize="276"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="158" sampleSize="279"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="149" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="24" sampleSize="140"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-12.15" sampleSize="241" stdDev="13.412886937568661"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-12.39" sampleSize="244" stdDev="13.402388443855818"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-13.42" sampleSize="242" stdDev="13.409572998421687"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-11.1" sampleSize="250" stdDev="13.408057279113928"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.21" sampleSize="120" stdDev="13.408248207726466"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Chest pain"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Chest pain"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Chest pain"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Chest pain"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Chest pain"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="1" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis chronic"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis chronic"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis chronic"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis chronic"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis chronic"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Coronary artery disease"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Coronary artery disease"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Coronary artery disease"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Coronary artery disease"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Coronary artery disease"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="1" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dyslipidemia"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="10" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dyslipidemia"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="11" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dyslipidemia"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="16" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dyslipidemia"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="10" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dyslipidemia"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="3" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epilepsy"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epilepsy"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epilepsy"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epilepsy"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epilepsy"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="13" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="9" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="16" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="9" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="10" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Inguinal hernia"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Inguinal hernia"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Inguinal hernia"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Inguinal hernia"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Inguinal hernia"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemia"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemia"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemia"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemia"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemia"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="1" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Lower respiratory tract infection"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Lower respiratory tract infection"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Lower respiratory tract infection"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Lower respiratory tract infection"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Lower respiratory tract infection"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myelodysplastic syndrome"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myelodysplastic syndrome"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myelodysplastic syndrome"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myelodysplastic syndrome"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myelodysplastic syndrome"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myocardial infarction"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myocardial infarction"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myocardial infarction"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myocardial infarction"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myocardial infarction"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="23" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="19" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="32" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="18" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="13" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pneumonia"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pneumonia"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pneumonia"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pneumonia"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pneumonia"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="8" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="2" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="3" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Shock"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Shock"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Shock"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Shock"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Shock"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Status asthmaticus"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Status asthmaticus"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Status asthmaticus"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Status asthmaticus"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Status asthmaticus"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Transient ischaemic attack"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Transient ischaemic attack"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Transient ischaemic attack"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Transient ischaemic attack"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Transient ischaemic attack"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="141"/>
                        <category name="45-64" rate="758"/>
                        <category name="&gt; 64" rate="376"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="32"/>
                        <category name="45-64" rate="173"/>
                        <category name="&gt; 64" rate="78"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="29"/>
                        <category name="45-64" rate="187"/>
                        <category name="&gt; 64" rate="67"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="37"/>
                        <category name="45-64" rate="161"/>
                        <category name="&gt; 64" rate="87"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="32"/>
                        <category name="45-64" rate="153"/>
                        <category name="&gt; 64" rate="97"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Placebo QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="11"/>
                        <category name="45-64" rate="84"/>
                        <category name="&gt; 64" rate="47"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="635"/>
                        <category name="Male" rate="640"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="150"/>
                        <category name="Male" rate="133"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="141"/>
                        <category name="Male" rate="142"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="136"/>
                        <category name="Male" rate="149"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="142"/>
                        <category name="Male" rate="140"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Placebo QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="66"/>
                        <category name="Male" rate="76"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
            </measurements>
            <epochs>
                <epoch name="Randomization">
                    <notes/>
                </epoch>
                <epoch name="Main phase">
                    <notes/>
                </epoch>
            </epochs>
            <activities>
                <studyActivity name="Randomization">
                    <activity>
                        <predefined>RANDOMIZATION</predefined>
                    </activity>
                    <usedBy epoch="Randomization" arm="Azilsartan Medoxomil 20 mg QD"/>
                    <usedBy epoch="Randomization" arm="Azilsartan Medoxomil 40 mg QD"/>
                    <usedBy epoch="Randomization" arm="Azilsartan Medoxomil 80 mg QD"/>
                    <usedBy epoch="Randomization" arm="Olmesartan 40 mg QD"/>
                    <usedBy epoch="Randomization" arm="Placebo QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Azilsartan 20">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="20.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Azilsartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Azilsartan Medoxomil 20 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Azilsartan 40">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="40.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Azilsartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Azilsartan Medoxomil 40 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Azilsartan 80">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="80.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Azilsartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Azilsartan Medoxomil 80 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Olmesartan">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="40.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Olmesartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Olmesartan 40 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Placebo">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="0.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Placebo"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Placebo QD"/>
                    <notes/>
                </studyActivity>
            </activities>
            <notes>
                <note source="CLINICALTRIALS">NCT00696241</note>
                <note source="MANUAL">This is one of the "main studies" supporting the Edarbi application for monotherapy identified in the EMA EPAR available at:

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002293/WC500119206.pdf

Retrieved from ClinicalTrials.gov using the Takeda internal study identifier 491-008.</note>
            </notes>
        </study>
    </studies>
    <metaAnalyses/>
    <benefitRiskAnalyses/>
</addis-data>
